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Objectives. We sought to determine the effect of nifedipine
gastrointestinal therapeutic system (GITS) or atenolol on isch-
emic left ventricular dysfunction induced by mental stress.
Background. The efficacy of conventional antianginal therapy
in preventing myocardial ischemia induced by mental stress is
unknown.
Methods. Nifedipine GITS, atenolol and placebo were admin-
istered to 15 subjects with stable angina in a double-blind
crossover trial. Subjects underwent a series of mental stressors at
the end of each treatment. Radionuclide ventriculography was
performed at baseline and at peak mental stress. Other measured
variables included time to ischemia on exercise treadmill testing,
ischemia on 48-h ambulatory electrocardiogram (ECG) monitor-
ing, and resting and mental stress-induced levels of plasma
catecholamines, tissue plasminogen activator antigen, plasmino-
gen activator inhibitor-1 and platelet aggregability.
Results. Mental stress resulted in a significant increase in
plasma epinephrine and norepinephrine levels during each treat-
ment phase. Atenolol therapy was associated with lower baseline
and postmental stress rate-pressure product compared with ni-
fedipine or placebo. Therapy with either nifedipine GITS or
atenolol prevented the development of wall-motion abnormalities
and the decline in regional ejection fraction (EF) in the segment
with the largest deterioration in wall motion during placebo
therapy. Both medications prevented the decrease in global EF in
subjects who demonstrated at least a 5% fall in global EF on
placebo therapy. No therapy exerted a statistically significant
benefit on exercise performance or frequency of ischemia during
ambulatory ECG monitoring.
Conclusions. Both nifedipine GITS and atenolol are effective at
preventing mental stress-induced wall-motion abnormalities, al-
though the mechanisms may be different.
(J Am Coll Cardiol 1998;32:1680–6)
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Psychological factors negatively affect the clinical course of
patients with coronary artery disease (1–13). For example,
episodes of anger during daily life may induce myocardial
ischemia and infarction (6,10,11). Psychological stress associ-
ated with natural disasters such as the 1994 Los Angeles
earthquake (13) or wartime stress (14,15) may trigger acute
ischemic syndromes. Myocardial ischemia may be caused by
the catecholamine surge that accompanies acute mental stress
by increasing double product or inducing coronary vasocon-
striction (16). Acute myocardial infarction may be triggered by
catecholamine-induced plaque rupture or by induction of a
hypercoagulable state with resultant coronary thrombosis
(17–19).
Experimentally, mental stress can be induced by a variety of
stimuli such as a stress interview or simulated public speaking
(1,8,11,20–26), performance of mental arithmetic (1,7,8,11,25–
29) or the Stroop color word test (1,8,11,20,26,30). In some
patients with coronary artery disease, mental stress induced by
these procedures is associated with a significant decrement in
overall ejection fraction (EF) and/or new abnormalities in
regional wall motion on radionuclide ventriculography
(1,8,11,20,26,30) and less frequently with transient ST-segment
depression on ambulatory monitoring (2,28). In addition,
mental stress can induce transient perfusion defects on
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SESTAMIBI scintigraphy (29) and angiographic coronary
vasoconstriction (24).
The effects of anti-ischemia medication on myocardial
ischemia induced by mental stress has not been well-studied.
Some advocate beta-adrenoceptor blocking agents to limit the
increase in heart rate and blood pressure induced by mental
stress, whereas others suggest that calcium-channel antagonists
targeting the prevention of coronary vasoconstriction may be
more appropriate therapy. The purpose of this study was to
investigate the effects of nifedipine gastrointestinal therapeutic
system (GITS) or atenolol on ischemic left ventricular dysfunc-
tion and alterations in coagulation status induced by mental
stress. Serial “mental stress testing” was used in a crossover design
to allow for serial drug testing with nifedipine GITS, atenolol and
placebo. Assessment of wall-motion changes by radionuclide
ventriculography in response to mental stress served as the
primary end point; secondary end points included the effect of
these medications on left ventricular diastolic function, platelet
function and fibrinolytic activity in response to mental stress.
Methods
Subjects. Subjects were recruited from the outpatient car-
diology clinics at the Brigham and Women’s Hospital, Boston.
Inclusion criteria included age between 35 and 75, history of
stable angina pectoris, a positive exercise treadmill test (de-
fined as .1.0 mm flat or downsloping ST-segment depression
induced by exercise), coronary artery disease documented by
coronary angiography or by prior transmural myocardial in-
farction, and .2 episodes of ischemia on baseline 48-h ambu-
latory monitoring. Exclusion criteria included a history of
myocardial infarction or unstable angina within 3 months of
study entry, uninterpretable ST-segment morphology or con-
comitant severe illness. The institutional committee on human
research approved the study protocol.
Study protocol. This study was a randomized, double-
blind, placebo-controlled crossover study lasting 13 weeks per
patient. After a 1-week single-blind placebo run in-phase,
subjects were randomized to the first of three, 4-week-long
treatment regimens: nifedipine GITS (mean daily dose 88 6
22 mg), atenolol (mean daily dose 91 6 20 mg) or placebo.
Medications were titrated to maximally tolerated dosages
during the first 3 weeks of each 4-week regimen, and at the end
of the 4 weeks, the subjects were admitted to the Clinical
Research Center for testing. In a similar manner, subjects
completed two additional 4-week regimens in random-order
sequence.
The Clinical Research Center protocol involved an after-
noon admission and application of an ambulatory electrocar-
diogram (ECG) monitor with sleep beginning between 10 PM
and midnight. Subjects were awakened the following morning
at 8 o’clock, remaining supine for vital signs and blood tests
and transported to nuclear medicine for resting radionuclide
ventriculography and mental stress testing. During mental
stress testing, skin conductance level, heart rate, blood pres-
sure, stress and angina ratings were continuously monitored,
and the ambulatory monitor was continuously applied to
monitor for ST-segment depression. At peak mental stress as
determined by skin conductance, radionuclide ventriculogra-
phy was repeated. Following mental stress testing, subjects ate
and remained sitting for 2 h, followed by blood tests and repeat
vital signs. Finally, an exercise treadmill test was performed
with blood tests at peak exercise. After exercise testing,
subjects were discharged for an additional 24 h of ambulatory
ECG (AECG) monitoring, and then crossed over to the next
medication regimen.
Mental stress testing protocol. The mental stress protocol
consisted of three tests as described by Jacobs et al. (31): 1)
5 min of pressured arithmetic consisting of serial subtraction of
7 from a four-digit number with pressure to subtract faster and
criticism of mistakes; 2) Stroop Color Word test for 5 min
consisting of a sheet with four columns of words “red,”
“green,” and “blue” printed in ink of a nonmatching color with
instructions to name the ink color as quickly as possible; and 3)
a stress interview for 5 min in which subjects were asked to
discuss the area of their life that had been the most stressful,
with the interviewer probing the most emotionally laden
aspects of the patient. Mental arousal was monitored with skin
conductance level measured every 15 s with a Davicon C20
EDR (Davicon, Burlington, MA). Mental stress was titrated by
a psychologist to achieve a similar level of increased skin
conductance during each drug phase.
Radionuclide ventriculography. The subjects’ red blood
cells were labeled with 740 Mbq (20 mCi) 99m-technetium by
means of a semi-in vitro technique. Data were collected with
the use of a 20% window at 140 keV on a large field-of-view
camera (GE) equipped with a low energy, general purpose,
parallel-hole collimator. Six million counts were acquired in
the best septal left anterior oblique projection with 15-degree
caudal tilt. Software zoom 32 was used to minimize counts
from noncardiac structures. A gate interval of 610% was set,
and the studies were acquired in frame mode, 24 frames/cycle,
in 64 3 64 word mode. The studies were spatially filtered
frame by frame with a two-dimensional fast Fourier transfor-
mation.
An algorithm with automatic edge detection and auto-
matic background correction was used for computing the
volume-equivalent left ventricular time-activity curve. The
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resulting time-activity curve was temporally filtered by fit-
ting a four-harmonic series. Global systolic and diastolic
function expressed as: EF 5 (EDV [end diastolic volume] 2
ESV [end systolic volume]/EDV) 3 100%, peak ejection
rate (PER) in EDV/s units, peak filling rate (PFR) in both
EDV/s and SV (stroke volume)/s units, PFR/PER ratio, and
time to peak filling rate (TPFR) in milliseconds were
computed. Regional EF was determined by standardized
computer-assisted division of the left ventricle in six por-
tions, the outflow tract region was excluded, and for each of
the remaining five regions, time-activity curves and regional
EF were generated. Wall-motion values for each of these
five regions were also scored visually by two independent
observers by consensus using a 4-point scale: 3 5 normal,
2 5 hypokinetic, 1 5 akinetic, and 0 5 dyskinetic. Change in
wall-motion score and regional EF during nifedipine and
atenolol treatment was determined for the left ventricular
segment with the greatest deterioration in wall motion
during the placebo phase for each individual subject (“worst
segment analysis”). Finally, subjects were divided into two
groups based on whether global EF fell at least 5% with
mental stress (EF responders and nonresponders)
(11,21,32) and analyses were repeated.
Exercise testing and ambulatory ECG monitoring. Exer-
cise testing was symptom-limited using the standard Bruce
protocol. Ambulatory ECG (AECG) was performed with
Applied Cardiac Systems cassette recorders (Laguna Hills,
CA) and modified leads V5 and aVF. The ECGs were
analyzed on a CardioData MK4 playback system with modified
software (33). An episode of ischemia was defined as transient
ischemic ST-segment depression of at least 1.0 mm, lasting at
least 1.0 min, and separated from other episodes by at least
5.0 min.
Other testing. All subjects maintained a diary of angina
symptoms and nitroglycerin use for each treatment phase.
Blood tests consisted of a complete blood count, platelet
aggregation studies with ADP (adenosine diphosphate) and
epinephrine, tissue plasminogen activator (tPA) antigen, tissue
plasminogen activator inhibitor (PAI-1) and plasma epineph-
rine and norepinephrine levels.
Statistical methods. Baseline demographic variables were
summarized for all subjects and by the three treatment se-
quence groups. Comparability between treatment sequence
groups was evaluated using analysis of variance for continuous
variable and chi-square tests or Fisher’s exact test for categor-
ical variables. Treatment effects were analyzed using one-way
analysis of variance. The multiple comparisons procedure
utilized for these analyses was Fisher’s Least Significant Dif-
ference for multiple treatment groups. Pairwise comparisons
were made if and only if the overall F-test was significant.
Two-sided p values less than 0.05 were considered significant.
The study had 82% power to detect a change in overall
wall-motion score among the three treatment groups using an
effect size of 0.047.
Results
Subject population. There were 17 subjects (16 male) of
mean age 65.5 years (range 45–75 years). Angina duration was
a mean 4.7 years, and five subjects were NYHA (New York
Heart Association) class I, 11 subjects class II and 1 patient
class III. There were no differences across treatment sequences
regarding these demographic data. Fifteen subjects completed
all phases of the treatment protocol, one dropping out owing to
a myocardial infarction and another to patient preference.
Statistical analyses were performed based on subjects complet-
ing all phases of the study protocol. Subjects were divided into
two groups based on the change in overall ejection fraction in
response to mental stress during placebo treatment: “Ejection
fraction responders” (n 5 5) with a decrease in EF of $5%
and “ejection fraction nonresponders” (n 5 10) with an
increase or decrease of ,5%. The treatment sequence for the
five responders was nifedipine/atenolol/placebo (n 5 3) and
placebo/nifedipine/atenolol (n 5 2). The treatment sequence
for the 10 nonresponders was nifedipine/atenolol/placebo (n 5
3), placebo/nifedipine/atenolol (n 5 4) and atenolol/placebo/
nifedipine (n 5 3). Only one patient developed ST-segment
depression during mental stress testing, and no subjects devel-
oped angina.
Changes in catecholamine levels, skin conductance and
double product in response to mental stress. The results of
serum catecholamine levels, skin conductance and double
product in response to mental stress are shown in Table 1.
Serum epinephrine levels rose in response to mental stress,
although this increase was most prominent during placebo and
atenolol therapy, with a statistically insignificant increase dur-
ing nifedipine therapy. Serum norepinephrine levels rose sig-
nificantly in all groups in response to mental stress. In addition,
significant increases occurred in all subgroups in the degree of
autonomic arousal as measured by changes in skin conduc-
tance at peak mental stress from baseline, but no significant
difference occurred in the degree of arousal among treatment
groups. Atenolol therapy was associated with a lower double
product compared with placebo or nifedipine.
Changes in left ventricular systolic function in response to
mental stress. Global left ventricular function. Overall, the
mean global EF showed no significant change in response to
mental stress during any treatment period (Table 2). However,
when subjects were divided into groups based on changes in
global EF during placebo therapy, there was a significant
protective effect of both nifedipine and atenolol therapy in
group 1 subjects: that is, these two medications prevented the
fall in global EF noted during the placebo phase (Fig. 1). In
group 2 subjects, there was no significant change in global EF
associated with any therapy.
Regional left ventricular function. During placebo therapy,
there was a highly significant mean reduction in semi-
quantitative wall-motion score and in regional EF in response
to mental stress. On placebo therapy, eight subjects (53%)
developed new regional wall-motion abnormalities, compared
with six subjects during therapy with nifedipine and four
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subjects with atenolol (p 5 0.33). When the segment with the
greatest decrement in wall-motion score during placebo ther-
apy was analyzed according to treatment group, both nifedi-
pine and atenolol therapy prevented the mental stress-induced
deterioration in wall motion observed on placebo (Fig. 2, p 5
0.009, compared with placebo for both). Likewise, regional EF
decreased significantly in response to mental stress during
placebo (Fig. 2). Nifedipine therapy protected against this
deterioration (p 5 0.01) and atenolol therapy was associated
with a trend toward protection (p 5 0.08).
Changes in left ventricular diastolic function in response to
mental stress. As shown in Table 3, when changes in diastolic
function in response to mental stress were analyzed for the
three different treatment groups, nifedipine was associated
with improved peak filling rate on baseline (premental stress
testing) compared with placebo, and there was a trend
toward an improvement at baseline with atenolol therapy
compared with placebo. No significant effects of atenolol or
nifedipine occurred on the change (postmental stress minus
premental stress) in peak filling rates or change in time to
peak filling.
Changes in platelet aggregation, tPA antigen and tPA
inhibitor in response to mental stress. No significant changes
occurred in platelet aggregability to ADP or epinephrine or
tPA antigen levels in response to mental stress. During nifed-
ipine therapy only, there was a significant decrease in the level
of tPA inhibitor in response to mental stress.
Results of exercise testing and ambulatory ECG monitor-
ing. Except for lower resting and peak heart rate and peak
double product on atenolol therapy, there were no significant
differences in exercise test variables among treatments or when
subjects were divided into groups based on global EF response
to mental stress. Ischemia on ambulatory ECG (AECG)
monitoring was infrequent, and there were no significant
differences among treatments or patient groups in number of
episodes or total duration of ischemia.
Table 1. Results of Mental Stress Testing: Changes in Skin Conductance and Catecholamine Levels and Double Product
Placebo Nifedipine Atenolol p Value
Pairwise p Values
N/A N/P A/P
Skin conductance level (mS/cm2)
Resting Minimum 3.07 6 2.02 3.07 6 1.93 2.63 6 1.45
D Overall 5.44 6 4.55‡ 5.14 6 3.29‡ 4.06 6 3.68‡ 0.295
Group 1 6.46 6 5.83† 5.05 6 2.91† 6.52 6 6.21‡ 0.422
Group 2 5.09 6 4.51‡ 5.15 6 3.78‡ 3.12 6 1.42† 0.191
Epinephrine (pg/ml)
Overall
Baseline 36.55 6 30.79 36.64 6 22.29 41.07 6 20.88 0.821
D 16.64 6 4.81† 8.09 6 4.81 10.45 6 4.81* 0.421
Group 1
Baseline 21.14 6 20.19 30.20 6 8.56 39.60 6 26.10 0.300
D 15.23 6 6.27 2.34 6 6.27 9.00 6 6.27 0.432
Group 2
Baseline 45.11 6 33.25 40.22 6 27.03 41.89 6 19.12 0.760
D 15.98 6 5.94* 10.88 6 5.94 14.47 6 5.94* 0.823
Norepinephrine (pg/ml)
Overall
Baseline 232.20 6 124.83 283.53 6 115.09 188.93 6 86.38 0.005
D 137.38 6 21.13‡ 173.36 6 21.13‡ 123.26 6 21.13‡ 0.236
Group 1
Baseline 130.60 6 43.73 198.80 6 90.37 97.80 6 45.92 0.178
D 101.81 6 31.53* 128.08 6 31.53† 83.19 6 31.53* 0.647
Group 2
Baseline 283.00 6 121.61 325.90 6 104.84 234.50 6 61.22 0.062
D 135.19 6 28.09‡ 179.66 6 28.09‡ 138.32 6 28.09‡ 0.017 0.005 0.077 0.180
Double Product (bpm 3 mm Hg)
Overall
Resting 9094 6 5540 8783 6 1847 6984 6 1232 0.001 ,0.001 0.258 ,0.001
D 6696 6 2552‡ 6403 6 3077‡ 5303 6 1685‡ 0.053
Group 1
Resting 8706 6 888 8507 6 909 7294 6 1209
D 6395 6 1465‡ 5305 6 1002‡ 5203 6 1953‡ 0.71
Group 2
Resting 9184 6 2704 8825 6 2089 6659 6 1095
D 7061 6 3150‡ 7241 6 3756‡ 5700 6 1538‡ 0.115
Group 1 denotes ejection fraction responders, and group 2 denotes ejection fraction nonresponders (see text). D 5 change. *p , 0.05. †p , 0.01. ‡p , 0.001 peak
mental stress compared with baseline values.
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Discussion
The catecholamine surge associated with mental stress may
lead to transient myocardial ischemia either by causing coro-
nary vasoconstriction or by increasing myocardial oxygen de-
mand, and blocking either mechanism may be effective in
preventing the development of ischemia. Our data suggest that
both nifedipine GITS and atenolol are protective against
deterioration in overall and regional wall motion associated
with mental stress. Therapy with atenolol resulted in a lower
resting double product as well as lower peak double product
after mental stress, and hence atenolol may prevent wall-
motion abnormalities by reducing myocardial oxygen demand.
Nifedipine therapy improved regional wall-motion abnormal-
ities without reducing peak double product, and thus may have
prevented mental stress-induced coronary vasoconstriction.
Mental stress induced changes in skin conductance and
catecholamine levels. Our study followed the protocol devel-
oped by Jacobs and co-workers (31) using skin conductance as
an index of autonomic arousal. Significant and similar in-
creases occurred in skin conductance and plasma epinephrine
and norepinephrine levels after mental stress for all three
treatment phases, confirming that mental stress was adequately
induced in these serial examinations to allow for comparisons
among treatment groups (34). Using continuous monitoring of
skin conductance, we were able to tailor the magnitude of
mental stress to assure consistency of physiologic arousal
within each subject on serial tests. This approach was used
because therapy with nifedipine and atenolol did not allow the
use of heart rate or blood pressure to gauge the degree of
mental stress achieved.
Mental stress induced changes in global and regional left
ventricular systolic function. Other investigators have shown
changes in global left ventricular EF in response to mental
stress similar to those we observed, with a minority of subjects
showing significant decreases. For example, only 1 of 18
subjects in a study by Ironson and colleagues (6) demonstrated
.7% decrease in EF in response to stressful speaking or
Table 2. Results of Mental Stress Testing: Radionuclide Ventriculography
Placebo Nifedipine Atenolol p Value
Pairwise p Values
N/A N/P A/P
Global ejection fraction (%): all patients
Resting 58.33 6 7.68 62.07 6 8.36 61.80 6 6.71 0.16
Peak mental stress 57.07 6 6.86 60.00 6 7.58 59.93 6 9.13 0.39
D 21.27 6 5.64 22.07 6 5.04 21.87 6 5.63 0.94
p Value 0.461 0.270 0.247
Global ejection fraction (%): Group 1 Ejection fraction responders (n 5 5)
Resting 62.40 6 1.52 62.80 6 2.86 65.20 6 3.56 0.07
Peak mental stress 54.60 6 0.89 60.60 6 6.73 65.60 6 4.51 0.01
D 27.80 6 1.64 22.20 6 4.55 0.40 6 2.88 0.01 0.56 0.01 0.007
p Value 0.001 0.59 0.75
Global ejection fraction (%): Group 2 Ejection fraction nonresponders (n 5 10)
Resting 56.30 6 8.77 61.7 6 10.23 60.10 6 7.40 0.07
Peak mental stress 58.30 6 8.23 59.70 6 8.30 57.10 6 9.69 0.01
D 22.00 6 3.56 22.00 6 5.50 23.00 6 6.43 0.01 0.56 0.01 0.007
p Value 0.001 0.59 0.75
Wall-motion scores: Segment with largest decrease during placebo phase (all patients)
Resting 2.44 6 0.63 2.13 6 0.96 2.19 6 0.91
Peak mental stress 1.88 6 0.96 2.13 6 1.02 2.19 6 0.83
D 20.53 6 0.13 0.00 6 0.13 0.00 6 0.13 0.011 1.000 0.009 0.009
p Value ,0.001 0.99 0.99
Regional ejection fraction (%): Region with largest decrease during placebo phase (all patients)
Resting 58.53 6 15.80 56.67 6 17.88 57.80 6 13.39
Peak mental stress 44.87 6 12.82 54.20 6 16.20 52.80 6 14.07
D 213.67 6 10.25 22.47 6 9.32 25.00 6 12.58
p Value ,0.001 0.513 0.062 0.034 0.366 0.011 0.081
D 5 Change from resting to peak mental stress.
Figure 1. Change in global ejection fraction: Subjects with a decline of
$5% on placebo (n 5 5). Boxes indicate mean values, with error bars
demonstrating 1 SE unit. EF 5 left ventricular ejection fraction.
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mental arithmetic. In the original study by Rozanski and
colleagues (11), 59% of subjects demonstrated new regional
wall-motion abnormalities, but only 14 of 39 (36%) of subjects
had a fall in overall EF of at least 5%. We found that in five
subjects with a decline in global EF in response to mental
stress during placebo therapy, atenolol and nifedipine GITS
were protective. In addition, when the segment with the largest
decrement in regional wall motion or regional EF on placebo
therapy was analyzed separately for all 15 subjects, nifedipine
GITS and atenolol prevented the development of wall-motion
abnormalities.
Mental stress induced changes in left ventricular diastolic
function. In response to myocardial ischemia, changes in left
ventricular diastolic function may precede deterioration in left
ventricular systolic function and ECG ST-segment depression
in patients with coronary artery disease (35,36). The effect of
mental stress-induced ischemia on left ventricular diastolic
function has not been previously studied. Although baseline
peak filling rate was abnormal in our subjects, we were unable
to demonstrate a further deterioration associated with mental
stress, even when we separated subjects into groups based on
changes in systolic function. There are several possible expla-
nations for this negative result. First, our study may have
lacked power to detect small but significant changes in diastolic
function. Second, peak filling rate (PFR) is an index of global
diastolic function and may therefore be a poor measure of
regional diastolic dysfunction from regional ischemia. Third,
PFR determined by radionuclide ventriculography is a mea-
sure of rate of change in volume and may not accurately reflect
diastolic properties of the left ventricle in the absence of
simultaneous measurements of pressure (37). It is possible that
more sensitive invasive measurements would have detected
changes in diastolic function in response to mental stress in our
subjects.
Mental stress induced changes in platelet aggregation and
fibrinolytic activity. Changes in platelet aggregability (38)
and/or endogenous fibrinolytic activity (39–42) may be impor-
tant in the pathophysiology of acute myocardial infarction, and
the effect of mental stress on these parameters has been poorly
studied. Perhaps owing to lack of statistical power, we did not
observe changes in platelet aggregability in response to mental
stress. Malkoff et al. (43) reported an increase in ADP
secretion but no change in platelet aggregation to ADP in
response to mental stress. Grigani and colleagues (44) re-
ported a small increase in platelet aggregation to ADP asso-
ciated with mental stress. We did not observe changes in tPA
antigen levels associated with mental stress, although during
nifedipine therapy mental stress was associated with a decrease
in the level of PAI-1. These data are in contrast to those of
Jern et al. (45), who demonstrated a small increase in tPA
antigen and no change in tPA inhibitor associated with mental
stress during placebo therapy.
Study limitations. Our study was limited by a small sample
size that may have led to type II errors for some of the
secondary end points. However, previous investigators
Figure 2. Change in wall-motion score and regional ejection fraction:
Comparison of region with largest decrease during placebo phase for
all 15 subjects. See text for explanation of wall-motion scoring and
Table 2 for absolute values for wall motion and regional EF. Pairwise
comparisons are not statistically significant unless otherwise indicated.
EF 5 left ventricular ejection fraction. n 5 placebo; h 5 nifedipine;
0 5 atenolol.
Table 3. Results of Mental Stress Testing: Radionuclide Ventriculography Diastolic Variables




TPFR (msec) 187 6 15.3 177 6 10.8 191. 6 16.0 0.76
PFR (EDV/s) 2.01 6 0.12 2.32 6 0.15 2.13 6 0.15 0.03 0.13 0.03 0.15
D (Postmental stress–premental stress)
TPFR (msec) 20.0 6 19.0 22.5 6 11.7 23.8 6 11.4 0.44
PFR (EDV/s) 20.09 6 0.10 20.08 6 0.13 20.11 6 0.09 0.96
PFR 5 peak filling rate; EDV 5 end-diastolic volume; TPFR 5 time to peak filling rate.
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(1,9,12,20,26,30) have utilized similar numbers of subjects, and
the crossover design in our study increased statistical power.
Conclusions. Both nifedipine GITS and atenolol are effec-
tive in preventing the development of wall-motion abnormal-
ities or overall left ventricular dysfunction in response to
mental stress, though the two therapies display different mech-
anisms of action. Further studies are needed to determine
whether combination therapy with atenolol and nifedipine is
more effective than either agent administered as monotherapy
in the prevention of mental stress-induced ischemia.
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